Although immunotherapy has a promising clinical response in a small number of patients with mismatch repair deficient (dMMR) or MSI-H solid tumors, most patients with MSS or MSI-L solid tumors still do not benefit.44,45 To an effective antitumor response, tumor antigens have to be captured by DCs, processed into peptide fragments, and presented on DCs with MHC-I to prime CD8+ T cells.1 However, tumors exploit multiple escape mechanisms to decrease antigen presentation within TME. Here, CD8A is linked to neoplasm.